Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1483-31-4 | MDL No. : | MFCD00598097 |
Formula : | C8H5ClN2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | QSGNNXKJPIMRPO-UHFFFAOYSA-N |
M.W : | 180.59 | Pubchem ID : | 12267312 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 44.74 |
TPSA : | 38.92 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.31 cm/s |
Log Po/w (iLOGP) : | 2.27 |
Log Po/w (XLOGP3) : | 2.94 |
Log Po/w (WLOGP) : | 2.39 |
Log Po/w (MLOGP) : | 1.93 |
Log Po/w (SILICOS-IT) : | 2.58 |
Consensus Log Po/w : | 2.42 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.42 |
Solubility : | 0.068 mg/ml ; 0.000377 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.42 |
Solubility : | 0.0688 mg/ml ; 0.000381 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.0 |
Solubility : | 0.0181 mg/ml ; 0.0001 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.04 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
[ 51039-53-3 ]
2-Bromo-5-phenyl-1,3,4-oxadiazole
Similarity: 0.73
[ 829-35-6 ]
2-(4-methoxyphenyl)-1,3,4-oxadiazole
Similarity: 0.73
[ 1612-76-6 ]
5-Phenyl-1,3,4-oxadiazol-2-amine
Similarity: 0.71
[ 91063-19-3 ]
3-(Benzyloxy)-6-chloropyridazine
Similarity: 0.70
[ 99367-44-9 ]
Ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate
Similarity: 0.58
[ 91063-19-3 ]
3-(Benzyloxy)-6-chloropyridazine
Similarity: 0.70
[ 89466-38-6 ]
6-Chloro-3-methoxy-4-methylpyridazine
Similarity: 0.65
[ 1591827-16-5 ]
Methyl 6-chloro-3-methoxypyridazine-4-carboxylate
Similarity: 0.56
[ 51039-53-3 ]
2-Bromo-5-phenyl-1,3,4-oxadiazole
Similarity: 0.73
[ 829-35-6 ]
2-(4-methoxyphenyl)-1,3,4-oxadiazole
Similarity: 0.73
[ 1612-76-6 ]
5-Phenyl-1,3,4-oxadiazol-2-amine
Similarity: 0.71
[ 99367-44-9 ]
Ethyl 5-(4-methoxyphenyl)-1,3,4-oxadiazole-2-carboxylate
Similarity: 0.58
[ 276694-19-0 ]
2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,3,4-oxadiazole
Similarity: 0.52